https://www.minoryx.com/content/imgs/icono_rss.png https://www.minoryx.com/ Natal https://www.minoryx.com/ en Natal Mon, 12 Oct 2026 10:56:51 +0100 Mon, 12 Oct 2026 10:56:51 +0100 https://www.minoryx.com/media/european-commission-grants-marketing-authorisation-for-nezglyal®-(leriglitazone)-the-first-pharmacological-treatment-approved-for-cerebral-adrenoleukodystrophy-(cald)-a-rare-neurodegenerative-disease/ Tue, 22 Sep 2026 23:34:16 +0100 more info

]]> https://www.minoryx.com/media/minoryx_and_neuraxpharm_complete_enrolment_in_leriglitazone_pivotal_phase_3_trial_(calyx)_in_adult_patients_with_cerebral_adrenoleukodystrophy_(cald)/ Wed, 09 Sep 2026 11:38:07 +0100 more info

]]> https://www.minoryx.com/media/leriglitazone_receives_a_positive_chmp_opinion_for_the_treatment_of_cerebral_adrenoleukodystrophy/ Thu, 23 Jul 2026 19:30:13 +0100 more info

]]> https://www.minoryx.com/media/leriglitazone_maa_submitted_for_treatment_of_cald_has_been_validated_by_ema/ Wed, 23 Jul 2025 10:16:16 +0100 more info

]]> https://www.minoryx.com/media/minoryx_receives_a_eur_26.9m_grant_within_the_framework_of_the_european_ipcei_med4cure_project/ Thu, 17 Jul 2025 09:40:04 +0100 more info

]]> https://www.minoryx.com/media/results_from_nexus_interim_analysis_published_in_eclinicalmedicine/ Wed, 04 Jun 2025 16:10:08 +0100 more info

]]> https://www.minoryx.com/media/minoryx-announces-dosing-of-the-first-patient-with-leriglitazone-in-the-phase-2a-study-in-rett-syndrome/ Mon, 03 Mar 2025 14:40:13 +0100 more info

]]> https://www.minoryx.com/media/leriglitazone_has_met_the_primary_endpoint_in_nexus/ Wed, 11 Dec 2024 10:27:23 +0100 more info

]]> https://www.minoryx.com/media/leriglitazone_halts_disease_progression_in_adult_patients_with_early_cerebral_adrenoleukodystrophy_in_compassionate-use_study_published_in_brain/ Tue, 11 Jun 2024 13:50:06 +0100 more info

]]> https://www.minoryx.com/media/update_on_regulatory_review_of_nezglyal_in_the_eu/ Fri, 31 May 2024 12:53:42 +0100 more info

]]> https://www.minoryx.com/media/rare_disease_day_2024_special_film_launched/ Thu, 29 Feb 2024 08:26:56 +0100 more info

]]> https://www.minoryx.com/media/update_on_regulatory_review_of_leriglitazone_in_the_eu/ Fri, 26 Jan 2024 12:44:56 +0100 more info

]]> https://www.minoryx.com/media/minoryx_announces_enrollment_of_first_patients_with_cerebral_adrenoleukodystrophy_in_us_phase_3_clinical_trial_calyx/ Thu, 16 Nov 2023 11:02:47 +0100 more info

]]> https://www.minoryx.com/media/minoryx-gains-fda-approval-to-initiate-a-phase-3-clinical-trial-in-patients-with-cerebral-adrenoleukodystrophy/ Wed, 31 May 2023 10:12:02 +0100 more info

]]> https://www.minoryx.com/media/minoryx-presents-positive-interim-results-from-nexus/ Tue, 25 Apr 2023 11:13:28 +0100 more info

]]> https://www.minoryx.com/media/the-lancet-neurology-publishes-results-from-minoryx-therapeutics-phase2-3-advance-clinical-trial-of-leriglitazone-in-x-linked-adrenoleukodystrophy/ Fri, 20 Jan 2023 08:30:08 +0100 more info

]]> https://www.minoryx.com/media/leriglitazone’s-clinical-proof-of-concept-data-in-friedreich’s-ataxia-published-in-neurology-genetics/ Wed, 18 Jan 2023 17:17:45 +0100 more info

]]> https://www.minoryx.com/media/minoryx-and-neuraxpharm-announce-a-strategic-alliance-to-provide-a-new-therapy-for-rare-cns-disease-patients-in-europe/ Wed, 09 Nov 2022 20:22:15 +0100 more info

]]> https://www.minoryx.com/media/minoryxs-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy-(x-ald)/ Wed, 14 Sep 2022 12:25:46 +0100 more info

]]> https://www.minoryx.com/media/minoryx-raises-e51-million-to-support-marketing-authorization-application-and-launch-preparations-for-x-linked-adrenoleukodystrophy-(x-ald)-therapy/ Mon, 30 May 2022 19:48:27 +0100 more info

]]>